Compare Natera Inc. Common Stock (NTRA) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Procter & Gamble Co — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Procter & Gamble Co trades at $158.38 (market cap $355.46B). The key difference: Procter & Gamble Co is far larger — about 6.2× Natera Inc. Common Stock's market cap, and Procter & Gamble Co pays a 2.85% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Procter & Gamble Co for 132 Days on average.
| NTRA | PG | |
|---|---|---|
Market Cap | $57.03B | $355.46B |
Volume | 1,131,157 | 5,731,171 |
Sector | Health | Consumer Staples |
52-Week High | $425.64 | $167.18 |
52-Week Low | $179.42 | $138.10 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $56.18B | $381.30B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Procter & Gamble (PG) trades at $153.05, showing modest daily movement with a slight 0.1% decline. The stock maintains strong technical momentum with bullish moving averages and key support at $152. Fundamentally, PG demonstrates robust profitability with 18.44% net margins and consistent earnings beats, though valuation multiples remain elevated versus peers. Recent corporate developments include dividend declarations and a new WNBA partnership, while analyst sentiment leans positive with a $160.13 consensus target.
PG offers stable dividend income with 69 consecutive years of increases, supported by strong cash flow generation. However, premium valuation and modest revenue growth create near-term headwinds. The stock presents a defensive play amid market volatility, but investors should monitor margin pressures and competitive dynamics in consumer staples. Upside potential exists if the company maintains earnings momentum above expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
